Research Analysts Issue Forecasts for ATOS Q1 Earnings

Atossa Therapeutics, Inc. (NASDAQ:ATOS) – Analysts at Ascendiant Capital Markets issued their Q1 2026 EPS estimates for Atossa Therapeutics in a research report issued to clients and investors on Sunday, April 20th. Ascendiant Capital Markets analyst E. Woo anticipates that the company will post earnings per share of ($0.06) for the quarter. Ascendiant Capital Markets has a “Buy” rating and a $7.25 price objective on the stock. The consensus estimate for Atossa Therapeutics’ current full-year earnings is ($0.22) per share. Ascendiant Capital Markets also issued estimates for Atossa Therapeutics’ Q2 2026 earnings at ($0.06) EPS, Q3 2026 earnings at ($0.06) EPS and Q4 2026 earnings at ($0.06) EPS.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $7.00 target price on shares of Atossa Therapeutics in a research note on Wednesday, March 26th.

Atossa Therapeutics Price Performance

Shares of ATOS stock opened at $0.74 on Wednesday. The business has a 50-day moving average of $0.70 and a 200 day moving average of $0.99. Atossa Therapeutics has a 1-year low of $0.55 and a 1-year high of $1.81. The stock has a market capitalization of $95.33 million, a PE ratio of -3.35 and a beta of 1.46.

Atossa Therapeutics (NASDAQ:ATOS) last posted its quarterly earnings results on Tuesday, March 25th. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.06) by $0.01.

Institutional Investors Weigh In On Atossa Therapeutics

Large investors have recently made changes to their positions in the business. Gallagher Capital Advisors LLC purchased a new stake in Atossa Therapeutics in the fourth quarter worth $25,000. Millennium Management LLC purchased a new stake in shares of Atossa Therapeutics in the 4th quarter worth about $28,000. Two Sigma Advisers LP boosted its stake in shares of Atossa Therapeutics by 214.1% during the 4th quarter. Two Sigma Advisers LP now owns 42,400 shares of the company’s stock valued at $40,000 after purchasing an additional 28,900 shares in the last quarter. Intech Investment Management LLC boosted its stake in shares of Atossa Therapeutics by 224.0% during the 4th quarter. Intech Investment Management LLC now owns 62,844 shares of the company’s stock valued at $59,000 after purchasing an additional 43,449 shares in the last quarter. Finally, Wells Fargo & Company MN increased its position in shares of Atossa Therapeutics by 30.7% during the fourth quarter. Wells Fargo & Company MN now owns 71,720 shares of the company’s stock valued at $68,000 after buying an additional 16,853 shares during the period. 12.74% of the stock is currently owned by institutional investors.

About Atossa Therapeutics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.